Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 9
2017 8
2018 11
2019 11
2020 9
2021 6
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Metastatic Colorectal Cancer.
Passardi A, Marisi G, Ulivi P. Passardi A, et al. Among authors: marisi g. Cancers (Basel). 2021 Dec 17;13(24):6346. doi: 10.3390/cancers13246346. Cancers (Basel). 2021. PMID: 34944966 Free PMC article.
Recent Research on Gastrointestinal Carcinoma.
Rovesti G, Marisi G, Casadei-Gardini A. Rovesti G, et al. Among authors: marisi g. Cancers (Basel). 2021 Jan 18;13(2):333. doi: 10.3390/cancers13020333. Cancers (Basel). 2021. PMID: 33477500 Free PMC article.
Dynamic Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer.
Urbini M, Marisi G, Azzali I, Bartolini G, Chiadini E, Capelli L, Tedaldi G, Angeli D, Canale M, Molinari C, Rebuzzi F, Virga A, Prochowski Iamurri A, Matteucci L, Sullo FG, Debonis SA, Gallio C, Frassineti GL, Martinelli G, Ulivi P, Passardi A. Urbini M, et al. Among authors: marisi g. JCO Precis Oncol. 2023 Sep;7:e2200694. doi: 10.1200/PO.22.00694. JCO Precis Oncol. 2023. PMID: 37656949
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
Marisi G, Azzali I, Passardi A, Rebuzzi F, Bartolini G, Urbini M, Canale M, Molinari C, Matteucci L, Sullo FG, Debonis SA, Gallio C, Gallo G, Frassineti GL, Ulivi P. Marisi G, et al. Sci Rep. 2023 Aug 9;13(1):12921. doi: 10.1038/s41598-023-40220-7. Sci Rep. 2023. PMID: 37558720 Free PMC article. Clinical Trial.
Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A, Azzali I, Bittoni A, Marisi G, Rebuzzi F, Molinari C, Bartolini G, Matteucci L, Sullo FG, Debonis SA, Gallio C, Monti M, Valgiusti M, Muratore M, Rapposelli IG, Ulivi P, Frassineti GL. Passardi A, et al. Among authors: marisi g. Ther Adv Med Oncol. 2023 Dec 11;15:17588359231212184. doi: 10.1177/17588359231212184. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38107830 Free PMC article.
Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review.
Casadei Gardini A, Santini D, Aprile G, Silvestris N, Felli E, Foschi FG, Ercolani G, Marisi G, Valgiusti M, Passardi A, Puzzoni M, Silletta M, Brunetti O, Cardellino GG, Frassineti GL, Scartozzi M. Casadei Gardini A, et al. Among authors: marisi g. Oncotarget. 2017 Jul 22;8(39):66699-66708. doi: 10.18632/oncotarget.19449. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029548 Free PMC article. Review.
60 results